Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05979818 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Propranolol Hydrochloride in Combination With Sintilimab and Platinum-based Chemotherapy for Treatment of Advanced Non-small Cell Lung Cancer

Study acronym: BRIO
StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 19, 2024 (before its estimated August 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Dec 31, 2023 to Nov 13, 2024 · Study sites: 0 to 1v3 Show 2 more changesShow less
    • Start date changed from estimate of Dec 31, 2023 to Nov 13, 2024
    • Study sites: 0 to 1
  2. Start date: Aug 15, 2023 to Dec 31, 2023 Secondary endpoints revised (3)v2 Show 1 more changeShow less
    • Secondary endpoints revised (3)

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is a prospective single-center Phase I clinical study in patients with EGFR/ALK/ROS1 driver oncogene negative, and advanced or metastatic NSCLC. This study is to evaluate the efficacy and safety preliminarily in a small-size of propranolol hydrochloride in combination with sintilimab and platinum-based chemotherapy in first-line therapy. Propranolol hydrochloride is a beta- adrenergic blocking agent which is associated with augment of immune cell responses. Propranolol hydrochloride may improve the responses of immune checkpoint inhibitors in treating patients with advanced NSCLC.
Trial Details
NCT Number NCT05979818
Lead Sponsor Second Xiangya Hospital of Central South University
Collaborators: Innovent Biologics (Suzhou) Co. Ltd.
Conditions Non Small Cell Lung Cancer, Propranolol
Enrollment 6 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov